LoVo-luc Orthotopic Mouse Model Service for Colon Cancer

The LoVo-luc orthotopic mouse model deploys a luciferase-tagged human colorectal adenocarcinoma line derived from a metastatic lymph node deposit, offering a preclinical platform that captures the drug-resistant, EMT-prone, and immune-evasive phenotypes characteristic of advanced-stage disease. Alfa Cytology constructs and manages this model with authenticated LoVo-luc cell assets, precision cecal wall surgical implantation, and integrated bioluminescence imaging, providing researchers with a robust system for interrogating chemotherapy resistance reversal, anti-metastatic interventions, and tumor microenvironment modulation in the preclinical setting.

Overview of LoVo-luc Orthotopic Mouse Model for Colon Cancer

The LoVo cell line was originally isolated in 1976 by Drewinko and colleagues from a metastatic tumor nodule in the left supraclavicular region of a 56-year-old male patient with colorectal adenocarcinoma. Genetically, this line harbors an activating KRAS p.G13D mutation, biallelic APC truncating mutations (p.M1431CfsTer42 and p.R1114Ter), and a frameshift mutation in ARID1A, while retaining wild-type BRAF, wild-type TP53, and wild-type PIK3CA status. LoVo is classified as microsatellite instable (MSI-H) due to mismatch repair deficiency, aligns with the CMS1 (MSI-Immune) consensus molecular subtype, and exhibits a hyperdiploid karyotype with a modal chromosome number of 49. Morphologically, the cells present as well-differentiated epithelial cells forming acinar structures adorned with microvilli, glycocalyx, and intact desmosomal and tight junctions, with a doubling time of approximately 24–30 hours under standard culture conditions. The luciferase-expressing derivative, LoVo-luc, preserves the full parental mutational landscape while enabling quantitative photon flux measurements that track viable tumor burden in vivo.

Fig 1. Radiomic signature for monitoring treatment sensitivity in the LOVO-Luc2 model. (Connor, Kate, et al., 2026)

When implanted orthotopically into the murine cecal wall, LoVo-luc tumors recapitulate the glandular differentiation, mucin production, and invasive behavior of human metastatic colorectal adenocarcinoma. This anatomical configuration preserves the luminal microbiome interface, submucosal vascular plexus, and mesenteric lymphatic drainage, thereby supporting spontaneous dissemination to the liver, lung, and peritoneal cavity. Notably, LoVo exhibits intrinsic resistance to 5-fluorouracil driven by thymidylate synthase overexpression and ATP-binding cassette transporter upregulation, displays TGF-β-inducible epithelial-mesenchymal transition with increased Snail and ZEB1 expression, and harbors a B2M mutation that abrogates MHC-I surface presentation, conferring immune evasion capacity. These molecular attributes render the LoVo-luc orthotopic platform uniquely suited for preclinical evaluation of chemoresistance reversal strategies, EMT-targeted therapeutics, and immune-modulatory approaches in metastatic colorectal cancer.

Cell Line Information: LoVo-luc

The table below presents a comprehensive compilation of the biological, genetic, and technical specifications of the LoVo-luc human colorectal adenocarcinoma cell line, serving as a detailed reference for investigators designing preclinical studies in both in vitro and in vivo settings.

Our Services

Alfa Cytology delivers a comprehensive LoVo-luc orthotopic mouse model service purpose-built for investigating metastatic colorectal cancer biology and therapeutic resistance. Our offering encompasses authenticated LoVo-luc master cell bank sourcing, mycoplasma clearance, and expansion under monitored passage limits, followed by precision cecal wall surgical implantation in immunocompromised hosts. Longitudinal tumor surveillance is conducted via scheduled IVIS bioluminescence imaging, while endpoint analyses span tumor biometrics, histopathology, immunohistochemistry, EMT marker profiling, and molecular characterization of resistance mechanisms. Each protocol element—from implantation cell density to imaging cadence and tissue triage—is tailored to your compound mechanism and translational objectives, yielding datasets suitable for peer-reviewed publication and regulatory dossier compilation.

Workflow of LoVo-luc Orthotopic Mouse Model Construction

Assembly of the LoVo-luc orthotopic colon cancer model demands exacting surgical technique, rigorous cell line stewardship, and standardized imaging protocols to ensure consistent engraftment and quantifiable therapeutic readouts. The operational framework described below is executed within specific pathogen-free barrier facilities, advancing through the following sequential stages:

1. Cell Line Authentication and Luciferase Validation: LoVo-luc cells are revived from authenticated cryopreserved master stocks and expanded in Ham's F-12K medium supplemented with 10% heat-inactivated FBS. Prior to surgical deployment, cells undergo mandatory STR identity confirmation, mycoplasma PCR screening, and in vitro luciferase activity validation via D-luciferin substrate assay to verify reporter expression stability and signal linearity across the anticipated cell density range.
2. Host Selection and Preoperative Conditioning: Female or male athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice aged 6–8 weeks are selected based on study design requirements. Animals are housed in specific pathogen-free vivaria under controlled temperature (22 ± 2°C), humidity (50 ± 10%), and a 12-hour light/dark cycle, with ad libitum access to irradiated chow and acidified water. A minimum five-day acclimation period is observed, during which baseline body weights and clinical observations are documented.
3. Anesthesia and Aseptic Surgical Field Establishment: On the day of implantation, mice are anesthetized with 2–3% isoflurane inhalation delivered via nose cone, with anesthetic depth confirmed by absence of pedal withdrawal reflex. The ventral abdominal wall is shaved and sterilized with sequential povidone-iodine and 70% ethanol applications. Sterile surgical drapes are positioned to maintain an aseptic operative field, and ophthalmic ointment is applied to prevent corneal desiccation.
4. Cecal Exposure and Orthotopic Cell Deposition: A 1.0–1.5 cm midline laparotomy is performed to access the peritoneal cavity. The cecum is gently exteriorized using atraumatic forceps and kept hydrated with warm sterile PBS. A single-cell suspension of 1 × 10⁶ to 2 × 10⁶ viable LoVo-luc cells, resuspended in 25–50 µL of serum-free Ham's F-12K medium mixed 1:1 with growth factor-reduced Matrigel, is loaded into a 1 mL syringe fitted with a 30 G needle. The needle is inserted into the subserosal plane of the cecal wall at the anti-mesenteric border, and the cell suspension is slowly deposited to form a discrete submucosal bleb without mucosal perforation.
5. Hemostasis, Cecal Repositioning, and Abdominal Closure: The injection site is compressed gently with a sterile cotton swab for approximately 3 minutes to ensure hemostasis and prevent cell leakage into the peritoneal cavity. The cecal wall is inspected for integrity, then gently returned to anatomical position within the abdomen. The abdominal musculature is closed with absorbable 5-0 sutures in a continuous pattern, and the skin is apposed with surgical staples or tissue adhesive. Mice are transferred to a warmed recovery chamber and monitored until full ambulatory recovery.
6. Bioluminescence Imaging and Tumor Kinetics Surveillance: Beginning approximately 7–10 days post-implantation, tumor establishment is monitored via non-invasive bioluminescence imaging. Mice receive an intraperitoneal injection of D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Photon flux (photons/sec) is quantified within a standardized region of interest, with imaging frequency adjusted to study design—typically twice weekly during the growth phase and weekly during treatment phases. Conventional cohorts are additionally monitored by abdominal palpation and digital caliper measurement of externally palpable masses.
7. Stratified Randomization and Therapeutic Intervention: Once tumors achieve a predetermined bioluminescence signal intensity—typically 10⁶ to 10⁷ photons/sec—mice are stratified by tumor burden and body weight into treatment and vehicle control cohorts. Investigational agents are administered according to predefined dosing regimens, with routes selected based on pharmacokinetic properties and mechanism of action. Concurrent bioluminescence imaging continues to capture real-time therapeutic response kinetics.
8. Necropsy, Triage, and Multi-Platform Endpoint Analysis: At study termination, mice are humanely euthanized under deep anesthesia. The cecum and primary tumor are excised en bloc, photographed, and weighed. Tumor tissue is triaged for formalin fixation and paraffin embedding (H&E, IHC for Ki-67, CD31, E-cadherin, vimentin, Snail, ZEB1, thymidylate synthase, cleaved caspase-3), snap-freezing for Western blot or RNA-seq, and dissociation for flow cytometric analysis. Metastatic foci in mesenteric lymph nodes, liver, lung, and peritoneum are enumerated macroscopically and confirmed histologically.

Fig 2. LoVo-luc orthotopic mouse model construction workflow.

Case Study-LoVo-luc Orthotopic Mouse Model Development

In a recent preclinical investigation, the LoVo-luc orthotopic model was employed to evaluate a chemoresistance reversal strategy combining a novel thymidylate synthase inhibitor with a TGF-β receptor kinase antagonist in metastatic colorectal cancer. Following cecal wall implantation, tumor-bearing mice were stratified by bioluminescence signal and randomized into combination, thymidylate synthase inhibitor monotherapy, TGF-β inhibitor monotherapy, and vehicle control arms. Longitudinal in vivo imaging revealed progressive suppression of tumor photon flux in the combination cohort beginning at day 14 post-treatment initiation, whereas monotherapy arms showed only transient stabilization. Terminal histopathological analysis demonstrated markedly reduced thymidylate synthase immunoreactivity and diminished E-cadherin loss in combination-treated tumors, alongside attenuated vimentin and Snail expression indicative of EMT suppression. Metastatic nodules in the liver and mesenteric lymph nodes were significantly reduced in the dual-targeting group compared to vehicle controls. These findings illustrate the translational utility of the LoVo-luc orthotopic platform for dissecting chemoresistance mechanisms and evaluating combination strategies that concurrently target proliferative and migratory phenotypes in metastatic colorectal adenocarcinoma.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your LoVo-luc orthotopic model program provides access to a specialized preclinical infrastructure calibrated for metastatic colorectal cancer drug development. Our operational strengths include:

• Authenticated LoVo-luc master cell banks with documented STR profiles, mycoplasma negativity, and sustained luciferase expression stability across extended passage ranges.
• Standardized in vitro luciferase linearity assays ensuring quantitative signal-to-cell-number correlation prior to in vivo deployment, safeguarding imaging fidelity throughout the study duration.
• Experienced microsurgical teams proficient in cecal wall orthotopic implantation, achieving high tumor take rates with minimal perioperative complications and rapid postoperative recovery.
• On-site IVIS bioluminescence imaging infrastructure enabling scheduled longitudinal tumor monitoring with calibrated photon flux quantification and automated region-of-interest analysis.
• Comprehensive endpoint triage protocols encompassing EMT marker profiling (E-cadherin, vimentin, Snail, ZEB1), resistance mechanism characterization (thymidylate synthase, ABC transporters), and standard histopathological and molecular analyses.
• Flexible study architectures accommodating monotherapy, combination, and sequential dosing paradigms, with stratified randomization based on real-time bioluminescence tumor burden metrics.

Contact Us

If your preclinical program requires a rigorously validated LoVo-luc orthotopic model for evaluating chemoresistance reversal, EMT-targeted therapeutics, or anti-metastatic strategies against colorectal malignancy, the scientific team at Alfa Cytology stands ready to architect a tailored study framework aligned with your therapeutic targets and regulatory milestones. Reach out to us today to discuss your project parameters, request a detailed service quotation, or arrange a technical consultation with our colorectal cancer model specialists.

For research use only. Not intended for any clinical use.